Study M1008
Study name | Tian PJ 2022a |
Title | Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: a randomized clinical trial |
Overall design | The aim of this study was to assess the psychotropic potential of Bifidobacterium breve CCFM1025 in managing major depression disorder. Depression patients (n = 45) were randomly assigned to the placebo (n = 25) and CCFM1025 (n = 20) groups. The freeze-dried CCFM1025 in a dose of viable bacteria of 10^10 CFU was given to MDD patients daily for four weeks, while the placebo group was given maltodextrin. Fecal tryptophan metabolites were investigated for clarifying the probiotics’ mechanisms of action using UHPLC-MS/MS. |
Study Type | Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive symptom; Depressive symptom; Depressive symptom; |
Criteria for depression | HAMD-24 > 14 |
Sample size | 45 |
Tissue | Peripheral; Faece; Faece; |
Platform | MS-based; LC-MS: Acquity UPLC system (Waters, Milford, MA, USA) with tandem mass spectrometry; |
PMID | |
DOI | |
Citation | Tian P, Chen Y, Zhu H, et al. Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: a randomized clinical trial. Brain Behav Immun. 2022 Feb;100:233-241. |
Metabolite |
